Prepared By R.R. Donnelley Financial -- Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C., 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date Of Report (Date Of Earliest Event Reported): 09/29/2005
Myriad Genetics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Commission File Number: 0-26642
Delaware
|
|
87-0494517
|
(State or Other Jurisdiction of
|
|
(I.R.S. Employer
|
Incorporation or Organization)
|
|
Identification No.)
|
320 Wakara Way
Salt Lake City, Utah 84108
(Address of Principal Executive Offices, Including Zip Code)
801-584-3600
(Registrants Telephone Number, Including Area Code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))
Items to be Included in this Report
Item 8.01. Other Events
On September 29, 2005, Myriad Genetics, Inc. announced that it has discovered a gene that, if mutated, may be responsible for overeating in children. This gene, named COB1 by Myriad, is the first common gene mutation to be associated with childhood obesity or hyperphagia. The press release is attached hereto as an exhibit to this Current Report on Form 8-K and is being filed pursuant to this Item 8.01 as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits
(c) The following exhibit is filed with this report:Exhibit
Number Description
99.1 The Registrant's press release dated September 29, 2005.
Signature(s)
Pursuant to the Requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the Undersigned hereunto
duly authorized.
|
|
|
|
|
|
Myriad Genetics, Inc.
|
|
|
Date: September 29, 2005.
|
|
|
|
By:
|
|
/s/ Peter D. Meldrum
|
|
|
|
|
|
|
|
|
Peter D. Meldrum
|
|
|
|
|
|
|
|
|
President and Chief Executive Officer
|
|
|
Exhibit Index
Exhibit No.
|
|
Description
|
EX-99.1
|
|
The Registrant's press release dated September 29, 2005.
|